The Arthrex appointments clause case is back before the U.S. Court of Appeals for the Federal Circuit. This time, it’s calling into question not only Patent Trial and Appeal Board (PTAB) decisions, but also hundreds of thousands of patents issued in the past 14 months.

That’s because medical device company Arthrex Inc. is arguing that the USPTO’s method of choosing Commissioner of Patents Drew Hirshfeld to serve as interim director of the agency is unconstitutional and incompatible with the Federal Vacancies Reform Act of 1998 (FVRA).

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]